Healius Limited (DE:PGZ)
FRANKFURT:PGZ
Want to see DE:PGZ full AI Analyst Report?
PGZ Stock Chart & Stats
€0.31
€0.00(0.00%)
At close: 4:00 PM EST
€0.31
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.91
Previous CloseN/A
Volume0.00
Average Volume (3M)34.00
Market Cap
€222.43M
Enterprise Value€1.97B
Total Cash (Recent Filing)€51.60M
Total Debt (Recent Filing)€1.66B
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 26, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding726,155,800
10 Day Avg. Volume100
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.26
Price to Sales (P/S)0.11
P/FCF Ratio0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.46Price Target Upside48.52% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€861.94M
Bulls Say, Bears Say
Bulls Say
Essential Fee-for-service ModelHealius’s core fee-for-service pathology and imaging model targets essential, recurring healthcare demand that is less cyclical than discretionary services. Diverse payers (government, private insurers, out-of-pocket) and steady referral flows support predictable volumes and revenue resilience over a multi-month horizon.
Positive Operating Cash GenerationStable positive operating cash flow provides liquidity and operational flexibility despite accounting losses. Over 2–6 months this supports funding day-to-day operations, servicing near-term obligations and executing efficiency or restructuring actions without immediate reliance on external capital markets.
Scale And Clinical NetworkA national network of labs, collection centres and imaging clinics creates durable competitive advantages: referral relationships, geographic coverage and fixed-cost leverage. Scale enables efficiency, bargaining power with payers and the ability to invest in automation or quality initiatives that sustain margins over time.
Bears Say
Falling Revenue And LossesA meaningful revenue decline combined with negative net margins signals structural pressure on demand, pricing or mix. Persistent top-line deterioration reduces operating leverage benefits, constrains reinvestment, and complicates returning to sustainable profitability within a multi-month horizon without clear revenue drivers.
High LeverageElevated debt-to-equity raises refinancing, interest coverage and covenant risks. High leverage limits strategic flexibility, increases sensitivity to cash flow volatility and can force prioritization of debt service over growth or capex, impairing the company’s ability to invest in operations or respond to reimbursement changes.
Declining Free Cash FlowA >20% drop in free cash flow weakens capacity to reduce debt, fund capital projects or absorb margin shocks. When paired with operating losses, declining FCF undermines long-term solvency and increases reliance on external funding or asset disposals to restore balance-sheet health over the medium term.
Healius Limited News
PGZ FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest stock price was €0.28 and its highest was €0.91 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is €222.43M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Aug 26, 2026 which is in 112 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Feb 17, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of >-€0.001 by -€0.009.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Undervalued.
Does Healius Limited pay dividends?
Healius Limited does not currently pay dividends.
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is 0.02.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,155,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -€0.009 in its last earnings report, missing expectations of >-€0.001. Following the earnings report the stock price went up 6.383%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in DE:PGZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€0.46 (48.52% Upside)
€0.46 (48.52% Upside)
Blogger Sentiment
Bullish
DE:PGZ Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth €66.2K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-29.48%
Trailing 12-Months
Asset Growth
-45.09%
Trailing 12-Months
Company Description
Healius Limited
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
PGZ Stock 12 Month Forecast
Average Price Target
€0.46
▲(48.52% Upside)
Technical Analysis
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---